CatalystMarker
← board

NBP

distress 5/10 · elevated risk
$1.75+0%today-73% from 52w high
novabridge.com30 employeesFounded 2014Rockville, MDBiotechnology
Revenue
pre-revenue
Liquidity
$211M
Runway
1.1 yrs
Shares 1y
0%

Price & events

-55.1% over 6M
$1.47$2.73$3.98Jan 26Apr 26Jul 264.7Mrating: HC Wainwright & Co.: Buy (2026-04-08)rating: HC Wainwright & Co.: Buy (2026-03-16)rating: HC Wainwright & Co.: Buy (2026-02-06)
CatalystRating changeDilutionFinancingdashed = today
+0.3%
1D
-2.5%
1W
+8.4%
1M
-29.4%
3M
-55.1%
6M
-17.3%
1Y
+22.0%
2Y
-97.6%
5Y
-96.1%
All

Overview

Market Cap
$463.08M
Volume
195.79K
52 Week Range
$1.47 – $6.56
Total Shares
265.38M
Float Shares
63.28M
Short %
5.01%
% Held by Insiders
14.41%
% Held by Institutions
39.91%
RVOL
0.31x
Beta
1.45

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 1

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 265,377,891 · 2 offerings/1y · 0 PIPEs
  • 2025-10-30424B3offering
  • 2025-08-04424B5offering
  • 2025-07-11424B5offering
  • 2025-05-15EFFECTshelf_effective
  • 2025-05-02F-3shelf_registration
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

strong buy · target $8 (+358% upside) · 3 analysts
  • 2026-04-08HC Wainwright & Co.Buy
  • 2026-03-16HC Wainwright & Co.Buy
  • 2026-02-06HC Wainwright & Co.Buy
  • 2025-10-24BTIGBuy
  • 2025-10-17BTIGBuy
  • 2025-10-03Leerink PartnersOutperform

Competitors

  • none identified

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.